Qichen Medical Completes Pre-A Financing Round to Accelerate Development of Integrated Interventional Solutions for Cardiopulmonary Diseases

VCBeat (WeChat ID: vcbeat) recently learned that Qichen (Shanghai) Medical Device Co., Ltd. (hereinafter referred to as “Qichen Medical”) announced the completion of its Pre-A financing round, amounting to tens of millions of RMB.This round of financing was led by Chende Capital, with follow-on investment from RAYS.The proceeds from this round of financing will be primarily used for the company’s clinical trials, new product research and development, and management expenses.

Qichen Medical is a high-tech enterprise integrating R&D, production, and sales, specializing in medical devices for heart failure and pulmonary interventions.The company currently operates a 3,000-square-meter Class 10,000 cleanroom production workshop and a 600-square-meter R&D center. Equipped with comprehensive R&D and manufacturing facilities, it has achieved an integrated, self-sufficient production model spanning from raw materials to finished products. Furthermore, the company is outfitted with high-end precision testing instruments, such as shunt fatigue testers and high-efficiency gas chromatographs, to rigorously monitor and control key quality characteristics of its products.

All products in Qichen Medical’s portfolio are fully protected by independent intellectual property rights. The company holds over 100 patents in the fields of heart failure and pulmonary interventional medicine, with technological capabilities ranking among the leading levels in China and keeping pace with the most advanced global medical technologies for integrated cardiopulmonary care. Guided by a profound understanding of clinical needs, the founders and team at Qichen Medical are committed to developing systematic solutions for heart failure and pulmonary diseases tailored to diverse populations, requirements, and clinical scenarios. They have independently developed and established a range of products and platforms, including high-pressure cardiac shunt technology, a mitral stenosis dilation system, a ventricular volume reduction system, an automated cardiac informatics analysis platform, a pulmonary thrombectomy system, and devices for pulmonary hypertension volume reduction.

The TwiFlow™ Transcatheter Pulmonary Artery Embolectomy System is a large-bore embolectomy system independently developed by Qichen Medical in collaboration with the Cardiovascular Hospital of Xiamen University. Designed for transfemoral venous access, it is used to remove thrombi from the main pulmonary artery and its branches, thereby restoring pulmonary blood flow and improving clinical symptoms. This product offers significant benefits for patients with severe pulmonary embolism (PE), particularly those with acute PE. On May 14, 2022, the vascular surgery team led by Dr. Wang Yan, President of the Cardiovascular Hospital of Xiamen University, successfully performed a transcatheter pulmonary artery embolectomy using the TwiFlow™ system on a patient with acute pulmonary embolism.This marks the official launch of nationwide clinical studies for TwiFlow™.

As an emerging medical device for the treatment of heart failure, the SIRIUS AFR atrial shunt system isThe world’s first multi-layer braided atrial shunt, and also the first atrial shunt manufactured using a compression bonding process.SIRIUS AFR features a secondary intervention retrieval function, and its sheath has a pre-curved design; to date, some patients have completed the six-month follow-up.

Qichen Medical is actively engaging in global exchanges and collaborations, steadily advancing various internationally recognized certifications. Meanwhile, the company joins forces with leading medical experts both domestically and abroad to conduct in-depth research on technologies such as left ventricular volume reduction, striving to build an innovative platform with a global perspective.

Regarding this round of financing, Liang Yuchen, founder of Qichen Medicalstated: “We extend our sincere gratitude to Chende Capital and Rong’an Venture Capital for their support and recognition of the company. Since its inception, Qichen Medical has been dedicated to the clinical translation and application of technologies for cardiopulmonary functional recovery. By clearly defining surgical classifications to guide the selection of clinical devices and elucidate functional mechanisms, we simultaneously explore therapeutic strategies that address both cardiac and pulmonary needs in at-risk populations. Adhering consistently to the philosophy of ‘science-driven development with comprehensive coordination,’ and grounded in the pathophysiological principles of heart failure and pulmonary diseases, Qichen has independently developed a portfolio of innovative products. This effort promotes the translational application of cutting-edge technologies in the field of cardiopulmonary medicine, leveraging dual advantages in core technologies and accumulated expertise. Currently, Qichen is in its Series A financing round. Moving forward, the company will focus on advancing technical operations across clinical centers in multiple cities and continue to deepen its commitment to the research and development of independently innovated products, aiming to provide diverse solutions for patients with heart failure and pulmonary diseases.”

Chende Capital Investment Teamstated, “If there are still unmet needs in the field of vascular intervention in China that have not been addressed by medical devices, heart failure and pulmonary diseases are certainly among them. Qichen Medical has started with devices for heart failure treatment, exploring the clinical concept of combined cardiopulmonary therapy. Several innovative products developed by the company have already entered clinical stages. We are optimistic about this strategic layout and highly recognize Mr. Liang’s R&D and execution capabilities. We also look forward to the company continuing to launch new innovative products in these two fields, bringing more surprises and benefits to clinical practice and patients.”

RAYS Investment Team“He stated: ‘With population aging and shifts in the disease spectrum, unmet clinical needs in the fields of cardiac and pulmonary diseases in China are becoming increasingly prominent, creating an urgent demand for the development of minimally invasive treatment solutions. Guided by the principle of integrated cardiopulmonary therapy, Mr. Liang and his team are committed to delivering products that offer greater procedural convenience for physicians and improved long-term prognosis for patients. Combining forward-looking innovation with pragmatic execution, the company’s team is poised to continuously bring surprising advancements to clinical practice and contribute to accelerating the localization of high-end medical devices.’”

Chende Capital is an investment firm focused on innovative medical technologies and cutting-edge biotechnology sectors, managed and operated by a professional team with extensive experience in the healthcare industry. The firm manages multiple RMB and USD-denominated funds.

Chende Capital adheres to the investment philosophy of “focus, excellence, and reputation.” Leveraging its deep industrial resources in the healthcare sector and years of in-depth research and cultivation, the firm promptly identifies the latest international technological trends, seizes investment opportunities driven by technological innovation, and has successfully exited multiple projects. Committed to discovering top-tier enterprises with industry-leading potential, Chende Capital collaborates with entrepreneurs to build an industrial ecosystem and achieve mutual growth through its interconnected, win-win investment methodology and a precise, pragmatic post-investment value-creation system, thereby delivering optimal returns to its investors.

RAYS focuses on incubating and supporting innovative startups in the healthcare sector. Its currently initiated and managed medical funds are positioned as specialized early-stage venture capital, concentrating on the healthcare industry and investing in high-potential enterprises involved in medical devices, biotechnology, innovative drug development, and healthcare services.